Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

New Article Makes Case for EGFR Testing
Before Using Iressa for NSCLC Treatment

[May 28, 2008]

By Turna Ray

The study, which was paid for by Iressa maker AstraZeneca, found that the drug, when prescribed to a genetically targeted population, may be more effective than chemotherapy as a first-line treatment — potentially good news for EGFR test makers.

Login | Subscribe